Current status and progress of concurrent chemoradiotherapy in patients with locally advanced non-small cell lung cancer prior to the approval of durvalumab.
Tomoya FukuiShinji HosotaniItaru SodaTakahiro OzawaSeiichiro KusuharaMikiko I KakegawaMasashi KasajimaYasuhiro HiyoshiSatoshi IgawaMasanori YokobaHisashi MitsufujiMasaru KubotaMasato KatagiriJiichiro SasakiHiromichi IshiyamaKatsuhiko NaokiPublished in: Thoracic cancer (2020)
Prior to the approval of durvalumab, the clinical application of ICIs improved the outcome of patients with relapsed NSCLC after CRT for LA-NSCLC. The management of radiation pneumonitis remains a challenge following the approval of durvalumab.
Keyphrases
- locally advanced
- rectal cancer
- small cell lung cancer
- neoadjuvant chemotherapy
- drug administration
- squamous cell carcinoma
- current status
- radiation therapy
- phase ii study
- advanced non small cell lung cancer
- acute lymphoblastic leukemia
- acute myeloid leukemia
- diffuse large b cell lymphoma
- brain metastases
- radiation induced
- hodgkin lymphoma
- heart failure
- epidermal growth factor receptor
- cardiac resynchronization therapy
- lymph node
- tyrosine kinase
- double blind